XERS’ XP-8121 targets 2030 launch, $1—3B peak sales
XP-8121 is a once-weekly subcutaneous levothyroxine aimed at 3—5 million hypothyroid patients not controlled on oral therapy, with launch targeted for 2030 and peak sales potential of $1—3 billion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
XERS XP-8121 targets $1–3B peak sales by 2030 launch
XERS said XP-8121, a once-weekly injectable levothyroxine, aims for $1–3B peak sales, targeting 3–5 million hypothyroid patients inadequately controlled on oral therapy. An FDA-aligned pivotal trial is set to support approval and launch by 2030.